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Abstract
Common criteria for the diagnosis of drug resistance and the assessment of outcome are needed urgently as a
prerequisite for standardized evaluation and reporting of individual therapeutic responses in canine epilepsy. Thus,
we provide a proposal for the definition of drug resistance and partial therapeutic success in canine patients with
epilepsy. This consensus statement also suggests a list of factors and aspects of outcome, which should be considered
in addition to the impact on seizures. Moreover, these expert recommendations discuss criteria which determine the
validity and informative value of a therapeutic trial in an individual patient and also suggest the application of
individual outcome criteria. Agreement on common guidelines does not only render a basis for future optimization of
individual patient management, but is also a presupposition for the design and implementation of clinical studies with
highly standardized inclusion and exclusion criteria. Respective standardization will improve the comparability of
findings from different studies and renders an improved basis for multicenter studies. Therefore, this proposal provides
an in-depth discussion of the implications of outcome criteria for clinical studies. In particular ethical aspects and the
different options for study design and application of individual patient-centered outcome criteria are considered.
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Background
Therapeutic management of canine and feline patients
with epilepsy poses a particular challenge for the practi-
tioner. The challenge is related to the multitude of eti-
ologies as well as the high inter-individual variance in
the clinical picture of canine and feline epilepsies. More-
over, the response to standard therapeutic regimes dif-
fers tremendously between individual patients.
Standardization in the assessment and reporting of out-
come of therapeutic interventions is essential for several
reasons. In individual patients, standardized procedures in
the evaluation of therapeutic responses will guide practi-
tioners in the diagnosis of drug resistance as a basis for
the decision to continue with an alternate therapeutic re-
gime. Moreover, expert consensus based recommenda-
tions render a basis for common reporting schemes,
which can significantly improve the information content
of patient history documents e.g. in the case of referral to
a veterinary neurology specialist. Thus, one aim of this
consensus proposal is to provide expert recommendations
for the assessment of outcome in individual patients fo-
cusing on the impact on seizures but also considering
other relevant aspects of outcome. In addition, we provide
and discuss a list of criteria that determine whether a
therapeutic trial in an individual patient can be considered
adequate and informative. Respective guidelines will also
help to exclude pseudo-resistance (defined as lack of a re-
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Standardized assessment and reporting of therapeutic
outcome in individual patients also is a prerequisite for
the realization of scientifically proven clinical studies. In
general, it is of particular relevance for the informative
value of the study that strict inclusion and exclusion cri-
teria are considered in the enrolment of patients for
clinical studies evaluating a particular therapeutic re-
gime. For instance if the study plan is to enrol patients,
in which epilepsy proved to be resistant to monotherapy
with a specific antiepileptic drug, a common definition
of resistance as well as common criteria for an adequate
and informative trial are needed urgently. Thus, univer-
sal recommendations provided in this proposal will ren-
der a basis for an improved consideration of inclusion
and exclusion criteria, will help reduce study population
variance, and will thereby increase the significance of
study data sets and findings.
Considering the diversity of etiologies and phenotypes
of canine and feline epilepsy and considering the fact that
data from human patients indicate that therapeutic re-
sponses differ tremendously between patient subgroups
depending on etiology, epilepsy and seizures types, there
is a pressing need to perform clinical studies in respective
subgroups of canine and feline patients. Studies focusing
on epilepsy with a specific etiology will only be feasible in
the form of multicenter studies, which require common
schemes for outcome assessment. Thus, one purpose of
this consensus paper is to provide the scientific, practical
and ethical aspects to be considered in different types of
epilepsy study designs.
Assessment of outcome in individual patients
Impact on seizures: definition of drug resistance and of
therapeutic success in individual patients
Despite a high number of studies dealing with the clinical
issue of drug resistance, a common definition of drug re-
sistant epilepsy is lacking. In 2010, a Task Force established
by the International League against Epilepsy (ILAE) has
proposed a working definition for drug resistance in human
patients, which since then has been assessed in clinical
practice: “Drug resistant epilepsy is defined as failure of
adequate trials of two tolerated, appropriately chosen and
used antiepileptic drug schedules (whether as monother-
apies or in combination) to achieve sustained seizure free-
dom” [1]. This definition has been the source of much
debate in relation to human epilepsy, and is intended
mainly for epidemiological work rather than to guide indi-
vidual practice. A recent study evaluated and confirmed
the reliability and validity of the criteria provided by the
definition [2]. The question for veterinary neurology is
whether this definition is suitable for the specific conditions
in clinical veterinary practice and whether it can be applied
to classify the outcome in canine and feline patients.
There is agreement that seizure freedom is the primary
treatment goal in the therapeutic management of canine
and feline epilepsy patients (Fig. 1; Table 1). Striving for
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Fig. 1 Categorization of seizure control. Seizure freedom is the primary treatment goal in the therapeutic management of canine and feline
epilepsy patients. The additional category of partial therapeutic success takes into account that the prevention of seizure clusters or status
epilepticus, and a reduction in seizure frequency or seizure severity can be of significant clinical relevance in veterinary patients
Potschka et al. BMC Veterinary Research  (2015) 11:177 Page 2 of 13
complete seizure control is of utmost importance consid-
ering the consequences of recurrent seizures. Repeated
epileptic seizures can result in neuronal cell loss, persistent
neuro-inflammation, disturbance of blood-brain barrier
function, and functional alterations in neurotransmitter
receptors and ion channels [3–5]. Respective alterations
can contribute to the development of behavioral co-
morbidities, can contribute to a progressively increasing
intrinsic disease severity, and a declining responsiveness
to therapeutic interventions [6].
Sudden unexpected death in epilepsy (SUDEP) is a
rare event, which however puts the patient at risk with
each single seizure event [7, 8]. Although an overall de-
creased life-span has not been confirmed in a recent
study focusing on idiopathic epilepsy [9], several other
reports acknowledge a decreased life-span in canine pa-
tients with idiopathic and structural (=symptomatic) epi-
lepsy [10–12]. These reports indicate that euthanasia is
the major risk factor contributing to a decreased life-
span due to uncontrolled seizures [10–12], but sudden
unexpected death in epilepsy (SUDEP) and seizure-
related falls, injuries, or asphyxiation are also risk factors
in the management of canine patients contributing to in-
creased mortality rates [11, 13]. To our knowledge no
information is available yet about SUDEP and life ex-
pectancy in feline epilepsy patients.
The ILAE Task Force has acknowledged in their
proposal that “a therapeutic intervention may lead to a
clinically meaningful reduction in seizure frequency (or
severity) that stops short of seizure freedom” [1]. In view
of the fact that complete vs. incomplete seizure control
does not have the same implications and consequences in
veterinary patients as it has in human patients due to the
socioeconomic impact on daily lifestyles, and that thera-
peutic decisions have thus to be balanced with costs and
adverse effects, we included the category of partial thera-
peutic success as a secondary treatment goal in the classifi-
cation scheme that we suggest in this proposal (see 2.4)
(Fig. 1; Table 1). This decision also takes into consideration
that in the past AED induced remission for 1–3 years has
only been reported in 15 – 24 % of dogs with idiopathic
epilepsy in a wide range of studies focusing on different
dog breeds with epilepsy of various severity [11, 12, 14].
The additional category of partial therapeutic success
takes into account that a reduction in seizure frequency,
seizure severity, and the prevention of seizure clusters or
status epilepticus can be of significant clinical relevance in
veterinary patients (Fig. 1; Table 1). Regarding an impact
on seizure frequency it is difficult to set a %-based limit
for partial success, because the baseline seizure frequency
needs to be taken into consideration. Experience of veter-
inary neurologists suggests that patient caregivers, the
owners, often consider less than one seizure in 3 months
acceptable [15]. Thus, depending on the pretreatment seiz-
ure frequency a reduction of seizure density to a respective
seizure interval e. g. one seizure every 3 months can be
considered as a relevant effect. In addition, a reduction
in seizure severity can result in a clinically meaningful
success, if for instance spread of seizure activity e. g.
generalization of focal onset seizures is prevented so that
seizures remain focal. Moreover, the prevention of seizure
clusters or status epilepticus can significantly affect the
quality of life of the patient and the pet owner.
Partial therapeutic success can have a significant clin-
ical relevance in canine and feline patients also affecting
the owner’s decision for euthanasia. Nevertheless, we
propose to apply the ILAE Task Force definition for vet-
erinary patients thereby drug-resistant epilepsy is diag-
nosed if seizure freedom is not achieved with two
therapeutic trials. However, we suggest indicating for
each patient in which drug-resistant epilepsy has been
diagnosed if there was evidence for a partial therapeutic
success as outlined above.
Moreover, consideration should be given to the fact
that there might still be reasonable hope to achieve seiz-
ure freedom in patients in which several therapeutic tri-
als have failed. Respective evidence has been reported by
different groups performing studies in human patients
[16–18]. Neligan et al [17] concluded that about half of
the patients with apparent drug resistant epilepsy can
have relevant improvements in seizure control with fur-
ther drug changes. Based on these findings they dis-
cussed that the proposed ILAE Task Force definition
might be too restrictive [17]. Another study indicated
that childhood-onset epilepsy might require specific con-
siderations as 51 % of the patients with drug-resistant
epilepsy entered 5-year terminal remissions [18]. Despite
Table 1 Categorization of outcome in individual patients
Categories: seizure control
1. Seizure-free
2. Seizures continue with partial therapeutic success (specified: reduction
in seizure frequency including information on seizure incidence,
seizure severity, or reduction in frequency of seizure clusters and
status epilepticus)
3. Seizures continue without partial therapeutic success
4. Undetermined (specify reason)
Categories: tolerability
A. No adverse effects
B. Adverse effects
C. Treatment not tolerated (substantial adverse effects resulting in
discontinuation)
D. Undetermined (specify reason)
Consider that short-term and long-term success should be evaluated
and should be indicated as discussed in the text. As outlined in the text
respective outcome information should always include information
about the drug regime. Table modified from [1].
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the lack of respective, comprehensive data sets in veter-
inary medicine, we feel that it is important to avoid an
early classification of drug resistant epilepsy having a
negative impact on the clinician’s efforts to continue
with therapeutic trials in individual patients. Thus, we
suggest that the term drug resistant is always used along
with the specification ‘to which antiepileptic drugs’, e.g.
phenobarbital resistant, imepitoin resistant and/or brom-
ide resistant [19, 20].
The ILAE task force definition lists an ‘appropriately
chosen antiepileptic drug schedule’ as a presupposition
for outcome conclusions [1]. In human patients know-
ledge about pathophysiological mechanisms as well as
the outcome of clinical studies rendered the basis for
treatment guidelines, which list first line antiepileptic
drugs, adjunctive antiepileptic drugs, second line antiepi-
leptic drugs, and antiepileptic drugs that may worsen
seizures for different seizure types and epilepsy syn-
dromes [21, 22]. Unfortunately, there is a lack of know-
ledge about drug responsiveness of different seizure
types and of epilepsies with different etiologies in veterin-
ary medicine. Despite this fact we propose to keep the
term ‘appropriately chosen’ in the definition (see consen-
sus statement on treatment for recommendations [23]),
when applying it to veterinary patients, as we expect a
gain in knowledge in the near future and as it should also
motivate to study differential responsiveness in patient
subgroups and canine vs. feline patients in more detail.
Please note that criteria for an adequate and inform-
ative trial in individual veterinary patients are discussed
under 2.4.
Other criteria and aspects of outcome
Impact on neurobehavioral comorbidities
Experimental studies as well as studies in human pa-
tients point to a bidirectional link between epileptic
seizures and psychological symptoms [24]. In human
epilepsy patients the increased prevalence of psychiatric
disorders including attention deficit hyperactivity dis-
order, depression, and anxiety disorders has been attrib-
uted to the psychosocial burden of epilepsy but also to
epilepsy-associated molecular, cellular, and network al-
terations. Also, it is postulated that in some instances,
the epilepsy and the co-morbidities are both the result
of similar underlying mechanisms. A direct impact of
pathophysiological mechanisms of epilepsy on neurobe-
havioral comorbidities is further confirmed by findings
in animal models [25]. So far only limited information is
available about epilepsy-associated neurobehavioral al-
terations in veterinary medicine. In drug-naïve dogs di-
agnosed with idiopathic epilepsy the development of the
disease resulted in an increase in the behavioral scores
for Fear/Anxiety, Defensive Aggression, and Abnormal
Perception [26]. Following onset of medication
Defensive Aggression was attenuated, whereas other be-
havioral alterations became evident including Abnormal
Reactivity, Attachment Disorder, Demented Behavior,
and Apathetic Behavior [26]. These data underline the
need to evaluate the effect of a therapeutic regime on
patient’s behavior with a particular focus on a beneficial
impact on neurobehavioral comorbidities. Therefore, it
is necessary to further develop behavioral scoring sys-
tems validated for the assessment of epilepsy-specific be-
havioral comorbidities. The efforts by Shihab et al [26]
and Wessmann et al [27] render an important basis for
respective score sheets, which are needed urgently for
different types of epilepsy in canine and feline patients.
In this context the questionnaire developed for the ana-
lysis of behavior in Cavalier King Charles Spaniels with
neuropathic pain due to Chiari-like malformation should
be considered as an example questionnaire tailored for a
specific neurological disease [28].
It is emphasized that data need to be collected before
the initiation of therapy, because only this baseline infor-
mation will allow distinguishing between disease-
associated alterations as well as beneficial or detrimental
effects of antiepileptic drugs. Moreover, despite the fact
that controversial findings exist, it is recommended to
thoroughly investigate the endocrine status in particular
considering that thyroid function might be altered in as-
sociation with epilepsy development and antiepileptic
drug treatment, and that the functional state of the thy-
roid gland has a major impact on neurobehavior and
brain function [29–32].
Adverse effects
Tolerability issues constitute an important limiting fac-
tor in the therapeutic management of epilepsy in human
and veterinary patients [27, 33, 34]. As further discussed
below they can significantly contribute to the patient’s
burden and can thereby determine drug retention rates.
Thus, the extent and the course of adverse effects should
be closely monitored when assessing the overall outcome
of a therapeutic trial in an individual patient (Table 1).
In general, it is important to distinguish between dose-
related effects and idiosyncratic effects as well as between
transient and long-term effects. Repeated evaluation of
adverse effects is necessary during titration phases but also
during chronic therapy. It needs to be considered that
adjustment and selective tolerance to specific adverse
effects can occur, and that aging or development of multi-
morbidities might alter the predisposition of individual
patients.
Pharmacological targeting of central nervous system
hyperexcitability is of course prone to be associated with
central nervous system adverse effects. However, pro-
nounced inter-individual differences exist in the suscep-
tibility to respective effects. Sedation or apathy and
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other behavioral alterations as well as a disturbance of
motor function [35, 36], sleep patterns, and cognition
[37] are among the dose-dependent central nervous sys-
tem effects, which should be considered in a patient’s
evaluation. In addition, systemic effects need to be
assessed including gastrointestinal effects. Moreover, it is
well known that the exposure to specific antiepileptic
drugs can increase the risk to develop pancreatitis [38,
39], hepatopathy, blood dyscrasias [40, 41] and skin re-
actions. Specific attention to the following introduction
of a new antiepileptic drug should be drawn to the po-
tential development of antiepileptic drug hypersensitivity
syndrome [42–45] which may evolve into a life-
threatening situation and requires immediate modifica-
tion of the drug regimen.
Food intake, water intake, body weight gain or loss can
be affected by both, central and peripheral effects of an-
tiepileptic drugs. The introduction of standardized vali-
dated questionnaires based on Likert or VAS scores
which comprise a respective list of frequent and rare ad-
verse effects allowing repeated comparison during drug
treatment are highly recommended. Comparison with
the pre-drug baseline condition, data, and antiepileptic
drug levels is of particular relevance. Evaluation should
also include pre-drug baseline and post-drug laboratory
evaluation which should ideally include CBC, extended
biochemical serum profile, urine and adequate evalu-
ation of liver function (pre- and postprandial bile acids
or ammonia). Evaluation of thyroid function is also rec-
ommended but faces specific challenges.
In case of polytherapy, putative drug interactions re-
quire specific considerations when assessing the tolerabil-
ity of an antiepileptic drug regime. Despite a controversial
discussion, we recommend that the endocrine status is
carefully controlled as thyroid function might be affected
by the disease as well as its treatment, and might in turn
affect the general condition with a pronounced impact on
behavior as well as body weight.
In case of severe adverse effects resulting in discon-
tinuation of a specific therapeutic approach, this fact
should be documented in the patient’s files with the
classification ‘treatment-not-tolerated’ with information
about the specific drug or other approach tested e.g.
‘Phenobarbital not tolerated’.
Assessment of the impact on quality of life
The impact of a treatment regime on quality of life (QoL)
must be considered as a major factor for the evaluation of
outcome. Thereby, therapeutic management can affect
QoL in a dichotomous manner. Whereas improved seiz-
ure control can exert beneficial effects on QoL, adverse ef-
fects can contribute to the patient’s burden.
The World Health Organization (WHO) has defined
QoL as the individual’s perception of their position in
life in the context of the culture and value systems in
which they live and in relation to their goals, expecta-
tions, standards and concerns [46]. The International
Society for QoL Research considers health-related QoL
as the functional effect of a medical condition and/or its
consequent therapy upon a patient (http://www.isoqol.org).
They emphasize that health-related QoL is subjective and
multidimensional, encompassing physical and occupational
function, psychological state, social interaction and somatic
sensation. It is a matter of course that the assessment of
health-related quality of life in veterinary medicine is lim-
ited to just some selected dimensions and aspects from the
list of those considered in human medicine.
Whereas the development of standardized tools can
render a basis for patient-reported outcomes measure-
ment in human patients, assessment of the QoL of
veterinary patients poses an even greater challenge to
veterinary practitioners regardless of the indication. On
the other hand it is well known that the perception of a
veterinary patient’s QoL by the owner plays a major role
in important decisions regarding the therapeutic man-
agement of epilepsy or the decision for euthanasia of a
patient with difficult-to-treat or drug-resistant epilepsy.
Problems are associated with the fact that the owner’s
QoL can constitute a bias in the owner-based evaluation
of the QoL of veterinary patients with epilepsy. In this
context, it needs to be considered that caring for a dog
with idiopathic epilepsy proved to have a major impact
on the carer’s QoL [10, 27]. Thus, it is of particular rele-
vance to not only assess the patient’s QoL with owner-
based questionnaires but also to assess the carer’s QoL,
and consider both in interpretations. In this context, it is
of interest that the owner’s perception of their dog’s
quality of life proved to negatively correlate with the
amount of work required to care for the dog [47].
QoL evaluation should ideally be performed before
treatment onset, following treatment initiation, following
treatment adjustments regarding dose titration or drug
choice, and should be repeated on an annual basis.
Whereas patient-related questions in the questionnaire
developed by Wessmann et al [27] focused on the con-
trol of seizures and adverse effects of antiepileptic drugs,
owner-related key questions dealt with restrictions on
the carer’s life, frustrations of the carer, the owner’s dis-
taste of antiepileptic drug adverse effects, the carer’s
anxiety around the seizure event, and the perception of
rectal diazepam use. The efforts by Wessmann et al [27]
rendered a validated tool specific for canine idiopathic
epilepsy. Muñana et al [48] have applied a QoL assess-
ment in the evaluation of adjunctive levetiracetam effi-
cacy and tolerability. The questionnaire used in this
study was adapted from one previously described by
Lord and Podell [47]. Respective standardized QoL as-
sessment tools need to be evaluated and if necessary
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further specified for symptomatic epilepsies, and need to
be developed for feline patients.
Adequate and informative therapeutic trial – criteria
In order to allow valid conclusions about the individual
outcome, each therapeutic trial should have been used at
optimal doses to exclude pseudoresistance defined as the
lack of a response due to an inadequate dosing or treat-
ment regime. As in human medicine, pseudoresistance
can have multiple reasons in veterinary patients. First of
all the compliance of the patient’s owner should be con-
sidered and if in doubt should be controlled by plasma
concentration analysis. As also emphasized by Kwan et
al [1] for human patients, it is of particular relevance to
guarantee an adequate dosing with sufficient duration
including efforts for optimization of dosing and titration
to clinically efficacious and still tolerated doses. If relevant
based on the mechanism of action of an antiepileptic drug,
it is recommended to control steady-state concentrations
in veterinary patients with plasma sampling and analysis
of trough levels before the next drug administration. Stan-
dardized drug level monitoring schemes are in general
highly recommended. In a recent study comparing the ef-
fect of timing of blood collection on serum phenobarbital
concentrations in dogs, no difference was evident between
trough, 3-hour and 6-hour concentrations indicating that
timing of blood sampling is not as important when pheno-
barbital is administered twice daily [49, 50]. However,
timing of sampling is likely to be of relevance, when anti-
epileptic drugs marketed for veterinary patients have failed
to achieve seizure control resulting in the use of drugs de-
veloped and marketed for human patients. The pharmaco-
kinetic features of respective antiepileptic drugs are often
suboptimal for dogs and cats, and have often not been
studied in detail in veterinary patients. Thus, the choice of
adequate administration intervals requires careful consid-
eration and control by determining trough levels. Deter-
mining trough concentrations is also of particular interest,
if seizures predominantly occur during the night. More-
over, it needs to be considered that small changes in
plasma concentrations might adversely affect outcome in
an individual patients, while no statistical effect might be
observed in a larger study population.
This however also requires valid knowledge about the
therapeutic plasma concentration range in dogs and cats,
which is not available for all antiepileptic drugs, which have
been used in canine and feline patients. Moreover, putative
drug interactions need to be considered with polytherapeu-
tic regimens. Muñana et al [51] have recently reported
that concurrent administration of phenobarbital alone
or together with bromide significantly alters the disposition
of the antiepileptic drug levetiracetam compared to co-
administration of bromide alone. In line with previous
findings from healthy dogs [52], the findings pointed to the
fact that phenobarbital lowers maximum plasma concen-
trations reached and accelerates the clearance of levetirace-
tam in epileptic dogs [51]. A similar interaction with
phenobarbital has been shown for zonisamide [53, 54].
As pointed out above, seizure freedom is the primary
goal in the therapeutic management of epilepsy patients.
An intense discussion has dealt with the minimum dur-
ation of a therapeutic trial allowing conclusions about
seizure-freedom in the course of an intervention trial.
Being considered seizure-free has major implications for
a human epilepsy patient for instance affecting the al-
lowance to drive or to work in specific environments. In
veterinary medicine the main question is whether the
duration of a trial has been long enough to be inform-
ative, so that one can decide about continuing with an-
other intervention trial in the case of therapeutic failure.
Moreover, trial duration also has significant implications
for the design of clinical studies, which require specific
ethical as well as trial validity considerations as further
discussed below.
A task force established by the ILAE has proposed that
a patient should be considered seizure-free in response
to a new intervention once no seizure occurred “during
a phase of at least three times the duration of their lon-
gest pre-intervention interseizure interval in the preced-
ing 12 months or during 12 months, whichever is
longer” [1]. Evaluation during a time span of at least
three times the duration of their longest preintervention
interseizure interval has been reported to result in a
95 % certainty that the patient’s seizure frequency has at
very least been decreased [1]. However, it has also been
emphasized that this certainty is only reached in patients
with a high seizure frequency. The ILAE task force pro-
posal is based on the statistical principle referred to as
the ‘Rule of Three’, which dealt with the issue to calcu-
late confidence intervals for zero events [55, 56]. The
minimum duration of seizure freedom for 12 months
has been added by the Task Force in order to obtain in-
formation, if a clinically relevant sustained effect oc-
curred [1]. If seizure freedom of at least three times the
longest preintervention seizure interval has been reached
but for less than 12 months, the outcome regarding seiz-
ure control is considered “undetermined” until seizure
freedom lasts for at least 12 months [1]. More recently,
Westover et al [57] have stated that the “Rule of Three”
as an operational definition of seizure freedom might be
reasonable in many cases, but that in other common
cases a longer waiting time might be necessary. The au-
thors suggested a revised criterion for seizure freedom
which they termed the ‘Rule of Three-to-Six’ [57]. This
suggestion considers the pre-intervention probability for
therapeutic success, which for instance can be signifi-
cantly reduced in patients with a history of multiple
failed therapeutic trials. In veterinary medicine valid data
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is lacking so that it is not possible to reliably conclude
about pre-intervention probability. Thus, it is recom-
mended to consider the ILAE Task Force proposal as a
basis for seizure outcome classification in veterinary pa-
tients. However, the statistical limitations, which are
most pronounced in patients with low seizure frequen-
cies, need to be considered when drawing conclusions.
In this context, it is important to note that the devel-
opment of tolerance has been reported in canine pa-
tients during the course of a chronic antiepileptic drug
treatment regime. Thereby, one needs to distinguish be-
tween metabolic tolerance related to accelerated drug
metabolism and elimination rates and functional toler-
ance related to alterations in drug targets sites. Whereas
metabolic tolerance might be overcome by adjustment
of dosing or administration intervals, this might not be
possible with functional tolerance.
The phenomenon of tolerance also referred to as
the ‘honeymoon effect’ can result in relapse after pro-
longed periods of a pharmacological treatment. Tolerance
development has for instance been suggested by studies
with zonisamide or levetiracetam add-on regimens [58,
59]. However, in these studies the relapse or impairment
of seizure control occurred within 2 and 8 months follow-
ing initiation of the new therapeutic regime [58, 59]. Thus,
the fact that the seizure-free period should last at least
12 months according to the ILAE Task Force proposal
should account for most of the cases with tolerance devel-
opment in canine patients rather avoiding a bias of the
‘honeymoon effect’ on seizure outcome conclusion. How-
ever, it is also emphasized that relapse is possible later on,
and that a continued follow up of seizures during subse-
quent years is crucial in order to conclude about clinically
relevant long-term success. In this context, it is also im-
portant to consider that seizure reoccurrence during
therapy might also reflect ‘regression to the mean’ as pa-
tients often enter trials, when seizure frequency is high,
and for the first few months seizure frequency might
just be reduced due to the natural course of individual
seizure frequency fluctuation. Please note that the defin-
ition of short term and long term therapeutic success is
discussed in detail below (see subchapter on Outcome
criteria for clinical studies).
Several issues can result in the owners’ and practi-
tioners’ decision for discontinuation of a specific inter-
vention. In these cases, it is of utmost importance to
document the reasons for discontinuation in the pa-
tient’s files indicating whether tolerability issues, lack of
efficacy, lack of compliance, financial considerations or
other reasons resulted in the decision. Respective infor-
mation will be of relevance for future therapeutic man-
agement decisions throughout the patient’s life, and will
be of particular significance if the patient is enrolled in
future clinical studies.
Assessment of outcome: implications for clinical
studies
Ethical and general aspects
There is a great interest of owners of epileptic dogs to par-
ticipate in trials of new antiepileptic drugs and regimens.
This interest is driven by failures of available antiepileptic
drugs in a proportion of epileptic dogs and concerns
about possible side effects of antiepileptic drug treatment
[12, 60–62]. There is general consensus that an inform-
ative clinical trial of antiepileptic drugs should be con-
ducted in a controlled, blinded and randomized manner
in order to achieve a high level of evidence [63] and to ad-
just for placebo effects which may average up to 30 %
[64], and which have been explained by natural fluctua-
tions in seizure frequency; but underreporting of seizures
towards the end of the trial or improper patient selection
may also increase clinical outcome variability [65, 66].
This raises several ethical issues which are of relevance
to epileptic dogs and their owners. In particular, there
are concerns that participation in placebo-controlled
clinical studies may withhold the chance for successful
treatment by the next individual therapeutic trial, either
due to the use of placebo or because of the requirements
to stay on an ineffective drug regime for prolonged time
periods in order to complete the study with a sufficient
number of subjects and to assess monthly seizure fre-
quency within a fixed treatment period.
These issues may be approached by the use of direct
comparison head-to-head trials and application of out-
come parameters which allow individual study end
points. Comparative head-to-head trials compare the
effectiveness of the drug under investigation against an-
other drug, usually a licensed drug with proven effective-
ness against placebo considered the gold standard for
the specific indication (active control; e. g. phenobar-
bital) [67]. This approach should provide each study par-
ticipant with a highly effective antiepileptic drug, but has
the draw-back that the differences between the interven-
tional group and the control group are smaller than if
compared to placebo and that higher numbers of partici-
pants are required for demonstration of smaller effects.
Assessment of outcome in clinical studies requires defin-
ition of clearly defined primary outcome measures. The
primary outcome measure in AED trials is efficacy defined
by the drug’s influence on seizure occurrence, but toler-
ability, quality of life, compliance and retention rates
should also be assessed in informative clinical trials [65].
The use of individual outcome parameters in clinical
trials which define individual study end points will be
possible if clinical studies aim at seizure freedom [1].
This has been suggested in human medicine for a long
time (e. g. time to first seizure, time to nth seizure, or in-
dividual patient-centered outcome criteria including tol-
erability issues), but clinical studies utilizing these
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outcome parameters are rarely found and validation for
veterinary patients would be required [65, 66, 68].
A more detailed discussion about general aspects re-
garding the design of clinical studies is beyond the scope
of this paper. In this consensus statement we will focus on
outcome parameters, and will just shortly introduce the
different types of clinical studies because study design and
inclusion criteria will affect assessment of outcome.
Types of clinical studies
Clinical studies of AED therapy should clearly describe
the study goal and the study population in focus. The
two different types of AED treatment trials are: (1)
Evaluation of AED monotherapy, or (2) evaluation of ad-
junctive AED add-on therapy. The study populations in
focus for the two study designs differ by chronicity and
likelihood of a positive outcome: Evaluation of AED
monotherapy focusses on patients with new onset epi-
lepsy, while the study population for evaluation of AED
add-on therapy is more likely to be composed of epi-
lepsy patients with a history of recurrent seizures for
prolonged time periods up to several years and proven
refractoriness to several AEDs. Controlled randomized
clinical studies with inclusion of control groups provide
higher levels of evidence and are preferred to uncon-
trolled open label pilot studies of antiepileptic drug effi-
cacy. In the latter each patient serves as its own control
and seizure frequency during the intervention period is
compared to a comparable baseline period. Uncontrolled
open label studies cannot differentiate between drug ef-
fects, natural disease fluctuations (placebo response) and
systemic influences e. g. intensified patient care during
the treatment period which might affect seizure fre-
quency. Still, open label pilot studies allow preliminary
conclusions as to the potential efficacy of the drug under
investigation, and can provide baseline statistical data
for calculation of the necessary group sizes to conduct
meaningful controlled clinical studies with adequate
statistical power. The major reason why controlled ran-
domized clinical studies fail to show an existing effect is
inadequate statistical power, caused by high drop-out
rates, insufficient patient numbers in the intervention
and control group to show an effect of a given size, or
high placebo responses [48, 64]. Patient selection con-
tributes to the variance within and between treatment
groups and will be further outlined below as part of the
inclusion criteria. Clinical studies in epilepsy also differ
significantly by the types of controls, which are used in
the respective studies. These should be clearly described
to facilitate interpretation of the results. Four different
types of controls are distinguished: (1) placebo, which
should have a similar appearance as the drug, (2) pseu-
doplacebo, meaning that the active drug is provided to
the control group in a low dose which may not be
effective (3) active control (positive control, treatment
with an effective drug provided to the control group,
head-to-head trial) (4) pseudocontrol (control group
without any treatment; also termed negative control)
[69]. Often, for ethical reasons the only choice for a trial
in patients with new onset epilepsy can be an active
control trial [67]. In line with this concept, Boothe et al
[70] have performed a head-to-head trial comparing the
efficacy and tolerability of phenobarbital and bromide
as an initial monotherapy. During the development of
imepitoin as a new AED for canine epilepsy, several trial
types have been used in epileptic dogs [19]: (1) an open
(non-controlled) trial, comparing imepitoin with pheno-
barbital and primidone in newly diagnosed dogs with epi-
lepsy; (2) an open (non-controlled) trial, comparing add-
on with imepitoin with add-on with potassium bromide in
dogs resistant to treatment with phenobarbital and primi-
done; (3) a randomized controlled trial with imepitoin vs.
pseudoplacebo (low dose of imepitoin); (4) a randomized
controlled trial with imepitoin vs. primidone; and (5) a
randomized controlled trial with imepitoin vs. phenobar-
bital. The last trial type was used in a pivotal field trial for
approval of imepitoin by the European Medicines Agency
[20]. A randomized placebo-controlled trial for approval
in the U.S. is in progress. As an alternative the use of his-
toric controls is intensely discussed in human medicine
[71, 72]. However, due to alterations in study populations,
and placebo response rates over time and due to a pro-
nounced impact of study sites on outcome, the use of his-
toric controls also faces major issues. In veterinary
medicine, the paucity of well-controlled studies repre-
sents another limitation. In general, patients should be
assigned to the intervention and control groups in a
blinded and randomized manner to avoid any bias in pa-
tient selection. However, stratification of treatment
groups for disease severity and further parameters (e.g.
diagnosis, seizure type, appearance of cluster seizures,
age of onset, duration of seizures prior to treatment,
breed) may be warranted. Moreover, strict inclusion and
exclusion criteria need to be applied considering re-
spective parameters and clearly defining the study popu-
lation (Table 2).
In this context it should be mentioned that the pre-
ferred type of study varies by the intention of the re-
spective investigators e. g. regulatory ministries, drug
companies, or clinicians treating the respective patients.
The U.S. Food and Drug Administration (FDA) often re-
quires statistical proof of superiority to a drug with
known efficacy, European Medicines Agency (EMEA) re-
quires proof of noninferiority.
Outcome criteria for clinical studies
In human patients huge differences exist between epilep-
sies of different etiologies and seizure types regarding
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responsiveness to different interventions, while only lim-
ited data are available in veterinary neurology with re-
gard to different types of epilepsies or breed-specific
epilepsy syndromes. It is generally agreed that a gain in
knowledge can only be obtained by applying stringent
inclusion criteria and defined endpoints, which define
the patient groups under investigation and, furthermore,
set the base for large multicenter studies with adequate
statistical power. Inclusion criteria and outcome parame-
ters must be identical for the intervention and control
group, in order to avoid any bias which may influence
outcome assessment. Important inclusion criteria which
may influence outcome of clinical studies are outlined
shortly in Table 2, while the further discussion focuses
on the specific outcome parameters.
Regarding outcome criteria it is recommended to con-
sider all categories discussed above for individual pa-
tients, and to apply standardized evaluation tools for
assessment. Thus, the outcome assessment should not
only consider the impact on seizures (efficacy), but also
a detailed evaluation of adverse effects (tolerability) and
of the impact of the intervention on behavioral comor-
bidities, and on quality of life of the patient and care-
taker (Table 3). With regard to tolerability detailed data
on reasons for study drop-out should be provided for
each patient that exits prematurely. Furthermore reten-
tion rate is a clinical relevant parameter which reflects
Table 2 Important inclusion criteria which may affect outcome
Criteria for the diagnosis of epilepsy How exclusion of other episodic
events (paroxysmal dyskinesias,
tremors, episodic collapse etc.)
is achieved, which are likely not
to respond to interventions
with AEDs
Criteria to restrict the study
population under investigation
to specific patient groups,
breed-specific epilepsies,
specific etiologies
E. g. if restriction to patients
with idiopathic epilepsy, implies
to define specific measures and
examinations undertaken to
exclude other causes of epilepsy
that are known to influence
outcome in a significant manner.
These criteria should follow the
requirements for the diagnosis
of idiopathic epilepsy as defined
in a separate consensus statement.
Description of the specific
pharmacoresistance pattern of
the study population under




should follow previous consensus
in this paper, which may include
definition of minimum serum
concentrations, requirements for
measurement of trough levels and
definition of steady state periods
as deemed necessary based on
mechanism of action for the
specific drug for which
pharmacoresistance is defined.
Criteria to restrict the study
population to a specific
disease stage
Criteria to restrict the study
population under investigation
either to
• trials of AEDs in patients with
new onset epilepsy, or
• trials of AEDs in patients with
chronic refractory epilepsy
Criteria for pre-drug assessment
in trials of AEDs in patients with
chronic epilepsy
Definition of baseline data
(e.g. written seizure diary,
prospective, retrospective)
and duration of baseline
period for assessment of
median pre-treatment seizure
frequency, cluster seizure
frequency or assessment of
the longest seizure-free interval
in the year preceding study inclusion
Criteria to restrict the study
population to patients without
severe systemic disease which
will likely affect outcome
E. g. exclude severe preexisting
hepatic, renal, endocrine disease
Table 3 Summary of primary outcome endpoints which are
applicable to clinical studies and highlight different aspects of
outcome; modified from [65, 66, 73]
Outcome parameters
Efficacy
Conventional endpoints fixed treatment period
Seizure free rate (percentage
seizure freedom)a
no baseline data required
Short-term 24 weeks
Long-term 48 weeks – 3 years




(≥50 % reduction median seizure frequency often not clinically relevant)
Individual endpoints
Time to first seizure based on interseizure
interval
Time to second seizure





Adverse events to be assessed, also assess number
and reasons for drop-outs
Quality of life
Patient’s QOL score validated scores needed
Owner’s QOL score control groups important
Retention rate applicable to long-term studies
a Need to specify reliability of assessment: (A) freedom of generalized seizures
only or (B) freedom of generalized and focal seizures
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the percentage of patients adhering to the drug after
prolonged treatment periods and thus is considered a
useful parameter for combined assessment of efficacy,
tolerability and even quality of life. Regarding the inter-
vention’s impact on seizures as many data should be col-
lected as possible. These should include total number of
seizures, seizure days allowing calculation of median
seizure frequency and seizure day frequency and seizure
free intervals (days). Additional parameters that assess
severity (occurrence of clusters and average number of
seizure per cluster, status epilepticus, focal seizures vs.
generalized seizures, severity and duration of post ictal
signs) should be included. This would allow assessment
of outcome in concordance with current recommenda-
tions in human medicine. Conventional primary out-
come parameters in humans are seizure free rate,
median seizure frequency, and responder rate, whereby a
drug responder is defined by a > 50 % reduction in sei-
zures compared to baseline. However, this is generally
considered a very weak endpoint, also reached by pla-
cebo in many patients, so that many clinical studies pre-
fer at least 75 % reduction in seizure frequency. It
should be noted that responder rate may not be a clinic-
ally meaningful outcome parameter, while assessment of
the seizure free rate (percentage) is a hard outcome par-
ameter which is independent from baseline data and is
clinically relevant. Current ILAE guidelines request a ≥
20 % absolute difference in between treatment groups
for ascertainment of a clinically relevant positive out-
come [73, 74]. It remains debatable whether a 20 % dif-
ference in outcome constitutes a clinically relevant
difference in veterinary patients. A summary of outcome
criteria which highlight different aspects of the disease
and are currently discussed in human medicine is pro-
vided in Table 2. Study protocols and assessment
schemes should also collect information about putative
seizure precipitating events or factors (e.g. owner leav-
ing, excessive activity, transfer to kennel).
A consensus was reached within the group that de-
fined individual study end points based on individual
pretreatment seizure frequency are preferred and that
respective study designs should be further developed
and validated in accordance to suggestions for AED tri-
als in human patients [1]. Preferred endpoint was the
definition of short term success as seizure freedom for a
time-span exceeding three times the longest interseizure
interval (days) in the year preceding the study and for a
minimum of three months (time to 1st seizure) [1, 65,
66]. Thus, if seizure freedom is not achieved time to the
2nd or nth seizure was considered as an alternative out-
come parameter for add-on trials in patients with
chronic refractory epilepsy [1, 65]. In this setting, any
patient with continued seizures following a titration
phase will be classified as treatment failure and allowed
to exit the study. Consequently, patients with complete
freedom of seizures or extension of the interseizure
interval to three times the longest interseizure interval
and a minimum of three months will be considered
treatment success and treatment should thereafter be
continued to assess the seizure free rate e. g. the per-
centage of patients with short-term or long-term free-
dom of seizures [67].
The use of seizure freedom as a primary outcome par-
ameter follows current ILAE recommendations and has
been successfully applied as primary outcome parameter
in one veterinary study focusing on new onset epilepsy
(outcome described as percentage seizure freedom, short
term) [70]. With this approach differences in seizure fre-
quency, seizure days, seizure severity, clusters or status
epilepticus during a fixed time period between groups
should be considered secondary outcome parameters in
clinical studies which can define and describe partial
treatment success in patients with chronic epilepsy par-
ticipating in add-on trials of AEDs in which seizure free-
dom may be difficult to achieve.
Open questions remain as to the definition of short
term or long term treatment success and whether seiz-
ure freedom can be a realistic goal in chronic epileptic
patients with AED drug polytherapy. Consensus exists
that the minimum duration of 24 weeks for studies in
human patients only assesses short term response to
AEDs, is subject to the so-called honeymoon effect, and
does not adequately predict long-term outcome after
1 year, 2 years or 5 years of treatment. Thus, follow-up
of patients for up to one year or even longer is war-
ranted. Besides seizure frequency, dogs’ QoL, owners’
QoL, adverse effects affecting tolerability, retention rate
of AED, survival rates and number and costs of veterin-
ary visits are other outcome parameters which may be
specifically applicable to long-term clinical studies in
veterinary patients due to the shortened life span of dogs
and cats compared to humans and the specific human-
animal-bond, which is affected by the disease. Open
questions remain also to the reliable assessment of focal
seizures in clinical studies in veterinary patients. Can
these be reliably counted and assessed in clinical studies
in veterinary patients without use of invasive EEG based
recording tools? Should improvement in generalized but
not in focal seizures be rated as a positive outcome e. g.
partial treatment success? These thoughts are especially
important if seizure freedom is applied as the primary
outcome parameter.
Further important points to be discussed are whether
stratification of treatment and control groups for appear-
ance of cluster seizures, breed and age of onset should
be attempted. Specifically the frequent appearance of
cluster seizure events appears to characterize a difficult
to treat subpopulation in veterinary patients with
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idiopathic epilepsy [12, 62, 75]. Differences between cer-
tain dog breeds appear to exist in regard to the natural
course of the epilepsy, while the impact of other factors
(e. g. previous head trauma) on outcome needs yet to be
defined. However, a more detailed discussion about gen-
eral aspects regarding the design of clinical studies and
the influence of study design on outcome assessment is
beyond the scope of this paper and will be provided in a
separate publication.
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